Thursday, August 14, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Merck & Co.

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Pyxis Oncology anticipates having preliminary data from the Phase 1/2 combination study of MICVO in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in R/M HNSCC and other ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

MSD's plan to reduce its headcount by around 6,000, first revealed a couple of weeks ago, looks like it will start at its ...

Finally, add PepsiCo (NASDAQ: PEP) to your list of S&P 500 dividend stocks to buy and hold forever while you can plug into ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly ...

Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...

Merck & Co., Inc. recently reported robust earnings, yet the market response was lukewarm. Investors overlooked several positive aspects beneath the surface. Unusual expenses, totaling US$4.2 billion, ...

Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial ...